@article{9de48ae91712446a9e37e2676814a7a2,
title = "The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease",
keywords = "Chronic kidney disease, Hepatocellular carcinoma, Nonalcoholic fatty liver disease, Type 2 diabetes mellitus",
author = "Emily Truong and Mazen Noureddin",
note = "Funding Information: M. Noureddin has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novartis, Novo Nordisk, Allergan, Blade, EchoSens, Fractyl, Terns, OWL, Siemens, Roche diagnostic, and Abbott; M. Noureddin has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Shire, Viking, and Zydus; M. Noureddin is a minor shareholder or has stocks in Anaetos and Viking. Grant support: None.",
year = "2022",
month = may,
doi = "10.1016/j.cld.2022.01.008",
language = "English (US)",
volume = "26",
pages = "213--227",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "2",
}